1 |
Bailon, P., A. Palleroni, C. A. Schaffer, C. L. Spence, W. J. Fung, J. E. Porter, G. K. Ehrlich, W. Pan, Z. X. Xu, M. W. Modi, A. Farid, and W. Berthold (2001) Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha 2a for the treatment of Hepatitis C, Bioconjugate Chemistry 12, 195-202
DOI
ScienceOn
|
2 |
Harris, J. M., N. E. Martin and M. Modi (2001), PEGylation: A novel process for modifying pharmacokinetics, Clinical Pharmacokinetics 40, 539-551
DOI
ScienceOn
|
3 |
Pepinsky, R. B., J. L. Doreen, G. Alan, and etc. (2001),Improved pharmacokinetic properties of a polyethyleneglycol modified form of interferon-beta-1a with preserved in vitro bioactivity, The J. pharmacology and experimental therapeutics 297, 1059-1066
|
4 |
Kodera, Y., A. Matsushima, M. Hiroto, H. Nishimura, A.Ishii, T. Ueno, and Y. Inada (1998), PEGylation of proteins and bioactive substances for medical and technical applications, Progress Polymer Science 23, 1233-1271
DOI
ScienceOn
|
5 |
Kinstler, O. B., US patent, 19, 5824784 (1998)
|
6 |
Yamamoto, Y., Y. Tsutsumi, Y. Yoshioka, T. Nishibata, K. Kobayashi, T. Okamoto, Y. Mukai, T. Shimizu, S. Nakagawa, S. Nagata, and T. Mayumi (2003), Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity, Nature Biotechnology 21, 546-552
DOI
ScienceOn
|
7 |
Allen, D., R. Baffi, J. Bausch, J. Bongers, M. Costello, J.Dougherty, Jr. M. Federici, R. Garnick, S. Peterson, R.Riggins, K. Sewerin, and J. Tuls (1996), Validation ofpeptide mapping for protein identity and genetic stability, Biologicals 24, 255-275
DOI
ScienceOn
|
8 |
Takacs, M. A., S. J. Jacobs, R. M. Bordens, and S. J.Swanson. (1999), Detention and characterization ofantibodies to PEG-IFN-alpha 2b using surface plasmonresonance, J. Interferon and Cytokine Research 19,781-789
DOI
ScienceOn
|
9 |
Kim, C.S. and Lee, E.K. (2000), Effect of operating parameters in in-vitro renaturation of a fusion protein of human growth hormon and glutathione S transferase from inclusion body, Process Biochemistry, 36, 111-117
DOI
ScienceOn
|
10 |
Perry, C. M. and Blair, J. (2001),Peginterferon-alpha-2a (40kD), Drugs. 61, 2263-2288
DOI
|
11 |
Rubinstein, S., P. C. Familletti, and S. Pestaka (1981), Convenient assay for interferons, J. Virology 37, 755-758
|
12 |
Conover, C. D., R. B. Greenwald, A. Pendri and K. L.Shum (1999), Camptothecin delivery systems: the utilityof amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs, Anti-cancer Drug Design 14, 499-506
|
13 |
Reddy, K. R., T. L. Wright, P. J. Pockros, M. Shiffman, G. Eversom, R. Reindollar, M. W. Fride, P. P. Purdum III, D. Jensen, C. Smith, W. M. Lee, T. D. Boyer, A. Lin, S. Pedder, and J. Depamphilis (2001), Efficacy and safety of PEGylated(40 kDa) interferon alpha 2a compared with interferon alpha 2a in noncirrhotic patients with chronic Hepatitis C, Hepatology 33, 433-438
DOI
ScienceOn
|
14 |
Kinstler, O.B., Brems, D.N., Lauren, S.L., Paige, A.G.,Hamburger, J.B. and Treuheit, M.J. Charqacterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13, 996-1002 (1996)
DOI
|
15 |
Kinstler, O., G. Molineux, M. Treuheit, D. Ladd, C. Gegg(2002), Mono-N-terminal poly(ethylene glycol)-proteinconjugates, Advaced Durg Delivery 54, 477-485
DOI
ScienceOn
|
16 |
Liptakova, H., P. Kontsek (1990), Problem of recombinant interferon alpha 2-immunogenicity in theraphy, Do Redakcie Doslo 100, 139-143
|
17 |
Lee, B.K., Lee, J.D. and Lee, E.K. (2004), Solid-phase, N-terminus-specific, mono-PEGylation of Recombinant Interferon- -2a: Purification, Characterization, and Bioactivity, presented at ISPPP 2004, Aachen, Germany
|
18 |
Lee, B.K.,, Korean patent #0453185(2004)
|
19 |
Gillis, E. H., J. P. Gosling, J. M. Sreenan, and M. Kane (2002), Development and validation of a biosensor-based immunoassay for progesterone in bovine milk, J. Immunological Methods 267, 131-138
DOI
ScienceOn
|
20 |
Means, G. E., and R. E. Feeney (1995), Reductive alkylation of proteins, Analytical Biochemistry 224, 1-16
DOI
ScienceOn
|
21 |
Hinds, K. D. and S. W. Kim (2002), Effect of PEGconjugation on insulin properties, Advanced Drug Delivery Reviews 54, 505-530
DOI
ScienceOn
|
22 |
Corssmit, E. P. M., J. D. Metz, H. P. Sauerwein, and J. A.Romun (2000), Biologic responses to IFN-a administration in humans, J. Interferon and Cytokine Research 20, 1039-1047
DOI
ScienceOn
|
23 |
Zalipsky, S. (1995), Chemistry of polyethylene glycolconjugates with biologically active molecules, AdvancedDrug Delivery Reviews 16, 157-182
DOI
ScienceOn
|
24 |
Potera, C. (2003), Pegylation for improving polypeptidedrugs, Genetic Engineering News. 23, 58-60
|
25 |
Lee, H. S., I. H. Jang, S. H. Ryu, and T. G. Park (2003), N-Terminal site-specific mono-PEGylation of epithermal growth factor, Pharmaceutical Research 20, 818-825
DOI
ScienceOn
|
26 |
Ghorbel, B., A. S. Kamoun, M. Nasri (2003), Stabilitystudies of protease from bacillus cereus BG1, Enzyme and Microbial Technology 6261, 1-6
|
27 |
Wang, Y. S., S. youngster, M. Grace, J. Bausch, R. Bordens, and D. F. Wyss (2002), Structural and biological characterization of pegylated recombinant interferon alpha 2b and its therapeutic implications, Advanced Drug Delivery Reviews 54, 547-570
DOI
ScienceOn
|
28 |
Lofas, S., M. Malmqvist, I. Ronnberg and E. Stenberg (1991), Bioanalysis with surface plasmon resonance, Sensors and Actuators B 5, 79-84
DOI
ScienceOn
|
29 |
Hellman, U., C. Wernstedt, J. Gonez, and C. Heldin (1995), Improvement of an 'In-Gel' digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing, Analytical Biochemistry 224, 451-455
DOI
ScienceOn
|
30 |
Seely, J. E., Buckel, S. D., Green, P. D. and Richey, C. W. (2005), Making site-specific PEGylation work, BioPharm International, March 2005, p.30-41
|
31 |
You, C. H (2001), Solid-phase mono-PEGylation forfunctionally improved recombinant interferon-alpha-2a, M. S. Thesis, Dep. of Chemical Engineering, Hanyang University, Korea
|
32 |
Bailon, P., and W. Berthold (1998), Polyethylene glycol- conjugated pharmaceutical proteins, P. S. T. T. 1,352-356
|